Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

The Avalanche Approach

Currently, wet age-related macular degeneration is treated with frequent injections of anti-VEGF protein directly into the eyeball. This creates a burden for both patients and physicians, and limits access for those who are not able to comply with frequent visits and injections.

Learn More About The Avalanche Approach:

Avalanche Biotechnologies to Present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting

October 9, 2014

MENLO PARK, CA – October 9, 2014 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology 2014 Annual Meeting on Thursday, October 16, 2014 at 8:49 am CDT in Chicago, IL. Additionally, Dr. Chalberg will participate in the “IPOs in Ophthalmology – The Class of 2014 and Beyond” at 4:10 pm CDT.

Read More

Read All Avalanche News